Suzana Maria Fleury Malheiros
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Suzana Maria Fleury Malheiros has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Adrialdo José Santos
Universidade Federal de São Paulo, Brazil
2 shared publications - Andre Felix Gentil
Hospital Israelita Albert Einstein São Paulo SP Brazil
2 shared publications - Edson Amaro
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
2 shared publications - Fabiana de Campos Cordeiro Hirata
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
2 shared publications - Guilherme de Carvalho Campos
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
2 shared publications - Adriane Feijó Evangelista
Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, Brazil
1 shared publication
Latest Publications
- 24 July 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
Real-world disparities in molecular diagnosis of diffuse gliomas in Brazil: Insights from LACOG 0619
Background: Diffuse gliomas in adults are rare, aggressive central nervous system (CNS) tumors whose outcomes are strongly influenced by molecular features. In Brazil, data on epidemiology, molecular diagnostics, and survival are scarce, particularly following the WHO CNS 2021 classification. The LACOG 0619 RWD (Real-World Data) addresses this gap by characterizing Brazilian diffuse glioma patients and evaluating diagnostic disparities. Methods: This retrospective, multicenter cohort included adults (≥18 years) with histologically confirmed diffuse gliomas from 9 centers in Brazil (2010-2019). Reclassification followed WHO CNS 2021 criteria. Completeness of molecular workup was compared between public and private institutions. Results: A total of 828 patients were included (median age 52 years, 56.0% male, 57.6% from private centers). Glioblastoma was the most frequent histology (57%). The central finding was a marked disparity in access to molecular diagnostics: IDH (Isocitrate Dehydrogenase), 1p/19q, MGMT (O6-Methylguanine-DNA Methyltransferase), and Next-Generation Sequencing testing were far more frequent in private institutions. Although testing rates improved after 2016, <20% of eligible cases underwent IDH sequencing. Survival differed by histology and WHO 2021 criteria, with 5-year overall survival ranging from 20.2% in IDH-wildtype glioblastoma to 90.9% in IDH-mutant grade 2 gliomas (P < .001), confirming the prognostic impact of molecular testing. Conclusions: LACOG 0619 is the first and largest RWD to assess molecular diagnostic gaps in diffuse gliomas in Brazil. The study reveals profound inequities between public and private healthcare institutions, underscoring the urgent need to expand equitable access to molecular testing as an essential step toward enhancing patient care and ensuring inclusion in precision oncology.
- 24 July 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
Real-world disparities in molecular diagnosis of diffuse gliomas in Brazil: Insights from LACOG 0619
Background: Diffuse gliomas in adults are rare, aggressive central nervous system (CNS) tumors whose outcomes are strongly influenced by molecular features. In Brazil, data on epidemiology, molecular diagnostics, and survival are scarce, particularly following the WHO CNS 2021 classification. The LACOG 0619 RWD (Real-World Data) addresses this gap by characterizing Brazilian diffuse glioma patients and evaluating diagnostic disparities. Methods: This retrospective, multicenter cohort included adults (≥18 years) with histologically confirmed diffuse gliomas from 9 centers in Brazil (2010-2019). Reclassification followed WHO CNS 2021 criteria. Completeness of molecular workup was compared between public and private institutions. Results: A total of 828 patients were included (median age 52 years, 56.0% male, 57.6% from private centers). Glioblastoma was the most frequent histology (57%). The central finding was a marked disparity in access to molecular diagnostics: IDH (Isocitrate Dehydrogenase), 1p/19q, MGMT (O6-Methylguanine-DNA Methyltransferase), and Next-Generation Sequencing testing were far more frequent in private institutions. Although testing rates improved after 2016, <20% of eligible cases underwent IDH sequencing. Survival differed by histology and WHO 2021 criteria, with 5-year overall survival ranging from 20.2% in IDH-wildtype glioblastoma to 90.9% in IDH-mutant grade 2 gliomas (P < .001), confirming the prognostic impact of molecular testing. Conclusions: LACOG 0619 is the first and largest RWD to assess molecular diagnostic gaps in diffuse gliomas in Brazil. The study reveals profound inequities between public and private healthcare institutions, underscoring the urgent need to expand equitable access to molecular testing as an essential step toward enhancing patient care and ensuring inclusion in precision oncology.
- Open Access
- 28 April 2025
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 23, eAO1343
Quality assessment of clinical practice in neuro-oncology
Highlights ■ The molecular test according to the WHO classification of CNS tumors (gliomas) was performed in 100% (172) of patients. ■ Education on chemotherapy and informed consent for patients with brain tumors was carried out for 100% (130) of the patients who had an indication for chemotherapy treatment. ■ Approximately 87% of the patients with gliomas underwent postoperative cranial MRI. ■ A multidisciplinary approach, including molecular testing, was used for 35% of patients with glioma. ■ Thromboembolic events after
- 28 April 2025
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 23, eAO1343
Open AccessQuality assessment of clinical practice in neuro-oncology
Highlights ■ The molecular test according to the WHO classification of CNS tumors (gliomas) was performed in 100% (172) of patients. ■ Education on chemotherapy and informed consent for patients with brain tumors was carried out for 100% (130) of the patients who had an indication for chemotherapy treatment. ■ Approximately 87% of the patients with gliomas underwent postoperative cranial MRI. ■ A multidisciplinary approach, including molecular testing, was used for 35% of patients with glioma. ■ Thromboembolic events after
- Open Access
- 29 December 2023
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 81 (12) , 1134-1145
Advances in diffuse glial tumors diagnosis
In recent decades, there have been significant advances in the diagnosis of diffuse gliomas, driven by the integration of novel technologies. These advancements have deepened our understanding of tumor oncogenesis, enabling a more refined stratification of the biological behavior of these neoplasms. This progress culminated in the fifth edition of the WHO classification of central nervous system (CNS) tumors in 2021. This comprehensive review article aims to elucidate these advances within a multidisciplinary framework, contextualized within the backdrop of the new classification. This article will explore morphologic pathology and molecular/genetics techniques (immunohistochemistry, genetic sequencing, and methylation profiling), which are pivotal in diagnosis, besides the correlation of structural neuroimaging radiophenotypes to pathology and genetics. It briefly reviews the usefulness of tractography and functional neuroimaging in surgical planning. Additionally, the article addresses the value of other functional imaging techniques such as perfusion MRI, spectroscopy, and nuclear medicine in distinguishing tumor progression from treatment-related changes. Furthermore, it discusses the advantages of evolving diagnostic techniques in classifying these tumors, as well as their limitations in terms of availability and utilization. Moreover, the expanding domains of data processing, artificial intelligence, radiomics, and radiogenomics hold great promise and may soon exert a substantial influence on glioma diagnosis. These innovative technologies have the potential to revolutionize our approach to these tumors. Ultimately, this review underscores the fundamental importance of multidisciplinary collaboration in employing recent diagnostic advancements, thereby hoping to translate them into improved quality of life and extended survival for glioma patients.
- 29 December 2023
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 81 (12) , 1134-1145
Open AccessAdvances in diffuse glial tumors diagnosis
In recent decades, there have been significant advances in the diagnosis of diffuse gliomas, driven by the integration of novel technologies. These advancements have deepened our understanding of tumor oncogenesis, enabling a more refined stratification of the biological behavior of these neoplasms. This progress culminated in the fifth edition of the WHO classification of central nervous system (CNS) tumors in 2021. This comprehensive review article aims to elucidate these advances within a multidisciplinary framework, contextualized within the backdrop of the new classification. This article will explore morphologic pathology and molecular/genetics techniques (immunohistochemistry, genetic sequencing, and methylation profiling), which are pivotal in diagnosis, besides the correlation of structural neuroimaging radiophenotypes to pathology and genetics. It briefly reviews the usefulness of tractography and functional neuroimaging in surgical planning. Additionally, the article addresses the value of other functional imaging techniques such as perfusion MRI, spectroscopy, and nuclear medicine in distinguishing tumor progression from treatment-related changes. Furthermore, it discusses the advantages of evolving diagnostic techniques in classifying these tumors, as well as their limitations in terms of availability and utilization. Moreover, the expanding domains of data processing, artificial intelligence, radiomics, and radiogenomics hold great promise and may soon exert a substantial influence on glioma diagnosis. These innovative technologies have the potential to revolutionize our approach to these tumors. Ultimately, this review underscores the fundamental importance of multidisciplinary collaboration in employing recent diagnostic advancements, thereby hoping to translate them into improved quality of life and extended survival for glioma patients.
- Open Access
- 9 November 2022
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 20, eAO0104
Comparative analysis of somatostatin analog uptake between successfully irradiated and non-irradiated meningiomas
Objective To evaluate whether there is a significant difference in somatostatin analog uptake in meningiomas treated or not with radiation therapy. Methods A cross-sectional study was performed comparing measurements of somatostatin analog (68Ga-DOTATATE) uptake in two independent groups of ten patients each – one consisting of patients with meningiomas previously treated with radiation therapy and another comprising patients who had never been submitted to radiation therapy. All patients underwent PET/CT and MRI scans in an interval shorter than 24
- 9 November 2022
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 20, eAO0104
Open AccessComparative analysis of somatostatin analog uptake between successfully irradiated and non-irradiated meningiomas
Objective To evaluate whether there is a significant difference in somatostatin analog uptake in meningiomas treated or not with radiation therapy. Methods A cross-sectional study was performed comparing measurements of somatostatin analog (68Ga-DOTATATE) uptake in two independent groups of ten patients each – one consisting of patients with meningiomas previously treated with radiation therapy and another comprising patients who had never been submitted to radiation therapy. All patients underwent PET/CT and MRI scans in an interval shorter than 24
- 1 July 2020
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 22 (7) , 957-966
Expression of GNAS, TP53, and PTEN Improves the Patient Prognostication in Sonic Hedgehog (SHH) Medulloblastoma Subgroup
- 1 July 2020
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 22 (7) , 957-966
Expression of GNAS, TP53, and PTEN Improves the Patient Prognostication in Sonic Hedgehog (SHH) Medulloblastoma Subgroup
- Open Access
- 1 June 2003
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 61 (2B) , 426-429
Associação de malformação vascular e gliomas: estudo de quatro casos
Entre os pacientes operados no Hospital São Paulo e acompanhados pelo setor de neuro-oncologia no período de 1991 a 2000, avaliamos a apresentação clínica, aspectos de imagem e características histopatológicas de 4 pacientes (2 homens; idade entre 15 e 52 anos) cujo diagnóstico histológico foi malformação vascular associada a glioma. O quadro inicial foi cefaléia progressiva com características de hipertensão intracraniana (em 3) e crises parciais motoras (em 1). O diagnóstico tomográfico inicial foi processo expansivo, sem que houvesse suspeita de malformação vascular pelo aspecto da imagem em nenhum caso. O exame histológico mostrou neoplasias de linhagem astrocítica associadas a malformações vasculares. Em nenhum paciente o componente vascular esteve localizado na intimidade da neoplasia. A associação de malformação vascular e gliomas é rara e deve ser caracterizada por nítida separação entre a malformação e a neoplasia, independente da vascularização própria do tumor.
- 1 June 2003
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 61 (2B) , 426-429
Open AccessAssociação de malformação vascular e gliomas: estudo de quatro casos
Entre os pacientes operados no Hospital São Paulo e acompanhados pelo setor de neuro-oncologia no período de 1991 a 2000, avaliamos a apresentação clínica, aspectos de imagem e características histopatológicas de 4 pacientes (2 homens; idade entre 15 e 52 anos) cujo diagnóstico histológico foi malformação vascular associada a glioma. O quadro inicial foi cefaléia progressiva com características de hipertensão intracraniana (em 3) e crises parciais motoras (em 1). O diagnóstico tomográfico inicial foi processo expansivo, sem que houvesse suspeita de malformação vascular pelo aspecto da imagem em nenhum caso. O exame histológico mostrou neoplasias de linhagem astrocítica associadas a malformações vasculares. Em nenhum paciente o componente vascular esteve localizado na intimidade da neoplasia. A associação de malformação vascular e gliomas é rara e deve ser caracterizada por nítida separação entre a malformação e a neoplasia, independente da vascularização própria do tumor.
- Open Access
- 1 March 2003
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 61 (1) , 129-133
Acidente vascular cerebral isquêmico após quimioterapia com cisplatina, etoposide e bleomicina: relato de caso
Relatamos o caso de um homem de 20 anos, com diagnóstico de tumor de células germinativas, que apresentou acidente vascular cerebral isquêmico durante quimioterapia com cisplatina, etoposide e bleomicina. Os casos relatados na literatura foram revisados, bem como os diferentes mecanismos fisiopatológicos implicados na toxicidade vascular deste esquema quimioterápico.
- 1 March 2003
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 61 (1) , 129-133
Open AccessAcidente vascular cerebral isquêmico após quimioterapia com cisplatina, etoposide e bleomicina: relato de caso
Relatamos o caso de um homem de 20 anos, com diagnóstico de tumor de células germinativas, que apresentou acidente vascular cerebral isquêmico durante quimioterapia com cisplatina, etoposide e bleomicina. Os casos relatados na literatura foram revisados, bem como os diferentes mecanismos fisiopatológicos implicados na toxicidade vascular deste esquema quimioterápico.